Home

Download

Statistics

Examples

About

Contact

	Fusion Gene Summary
	Fusion Gene Breakpoints
	Tumorigenic MoA (Mechanism of Action) Scenarios of Fusion Geness
	Fusion Genomic Features
	Fusion Gene ORF Annotations
	Fusion Protein Retained/Non-Retained Functional Features
	Fusion Transcript Sequences
	Fusion Protein Sequences
	Personalized Fusion Protein Sequences
	Fusion Gene Expressed Samples
	Related Drugs

Fusion gene:AGAP1_IFIH1 (FusionGDB2 ID:HG116987TG64135)

Fusion Gene Summary for AGAP1_IFIH1

Fusion gene summary

Fusion gene information	Fusion gene name: AGAP1_IFIH1
	Fusion gene ID: hg116987tg64135
		Hgene	Tgene
	Gene symbol	AGAP1	IFIH1
	Gene ID	116987	64135
	Gene name	ArfGAP with GTPase domain, ankyrin repeat and PH domain 1	interferon induced with helicase C domain 1
	Synonyms	AGAP-1\|CENTG2\|GGAP1\|cnt-g2	AGS7\|Hlcd\|IDDM19\|IMD95\|MDA-5\|MDA5\|RLR-2\|SGMRT1
	Cytomap	2q37.2	2q24.2
	Type of gene	protein-coding	protein-coding
	Description	arf-GAP with GTPase, ANK repeat and PH domain-containing protein 1Arf GAP with GTP-binding protein-like, ANK repeat and PH domains 1GTP-binding and GTPase-activating protein 1centaurin, gamma 2	interferon-induced helicase C domain-containing protein 1CADM-140 autoantigenDEAD/H (Asp-Glu-Ala-Asp/His) box polypeptideRIG-I-like receptor 2RNA helicase-DEAD box protein 116clinically amyopathic dermatomyositis autoantigen 140 kDahelicardhelicase
	Modification date	20240305	20240416
	UniProtAcc	.	.
	Ensembl transtripts involved in fusion gene	ENST00000304032, ENST00000336665, ENST00000409457, ENST00000409538, ENST00000428334,
Fusion gene scores	* DoF score	* DoF score (Degree of Frequency) = # partners X # break points X # disease types 59 X 23 X 29=39353	* DoF score (Degree of Frequency) = # partners X # break points X # disease types 5 X 9 X 7=315
	# samples	107	15
	** MAII score	** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score10) log2(107/3935310)=-5.20079091925792 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0	** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score10) log2(15/31510)=-1.0703893278914 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0
Context	PubMed: AGAP1 [Title/Abstract] AND IFIH1 [Title/Abstract] AND fusion [Title/Abstract]
Most frequent breakpoint	AGAP1(236403493)-IFIH1(163167443), # samples:1

Fusion gene breakpoints across AGAP1 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Fusion gene breakpoints across IFIH1 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Top

Fusion Gene Breakpoints for AGAP1_IFIH1

RNA-seq based exon junction arranged fusion gene breakpoints from 8 resources (TCGA, CCLE, cBioPortal, GenBank, ChimerDB, ChimerKB, ChildHoodFusions, and GTEx). For the expressed sample information, go to Fusion Gene Sample section.

Hgene	Hchr	Hbp	Tgene	Tchr	Tbp
AGAP1	chr2	236403493	IFIH1	chr2	163167443

DNA-seq based exon junction arranged fusion gene breakpoints from dbVar. For the expressed sample information, go to Fusion Gene Sample section.

Hgene

Hchr

Hbp

Tgene

Tchr

Tbp

SV type

Top

Tumorigenic MoA (Mechanism of Action) Scenarios of Fusion Genes for AGAP1_IFIH1

To generate these tumorigenic scenario annotations, we implemented a deduction-first, retrieval-later computational framework. The pipeline first applies rule-guided reasoning across ten core mechanistic categories (M1–M10) derived from fusion gene biology to infer candidate mechanisms, tumorigenic scenarios, targeting points, and targeting backgrounds. To ensure empirical accountability, a governed Python workflow retrieves literature candidates via NCBI E-utilities and Europe PMC using tiered searches. Using JSON Schema-constrained LLM evidence judges (GPT-5.6 Luna and Terra), retrieved articles are evaluated for specificity and confidence without de novo PMID generation. This produces two distinct versions: a strict version restricted to high- or medium-confidence fusion-specific evidence, and an extended version incorporating broader gene-, pathway-, and contextual evidence.

* We have 10 tumorigenic mechanism categories of fusion genes as shown below.

Constitutively Active Kinases, Catalytic Domain Dysregulation, & Transmembrane Ligand Fusions	Aberrant Chimeric Transcription Factor / Fusion Transcription Factor Activity	Epigenetic Reprogramming / Histone Modifier Dysregulation	Chromatin Remodeling Dysregulation	Condensate-Driven Transcriptional Rewiring / LLP	Promoter / Enhancer Hijacking	Dominant-Negative Antagonism	Cell Cycle / Checkpoint Bypass / RNA Processing Dysregulation	Subcellular Mislocalization / Spatial Dysregulation	Nuclear Body / Sub-organellar Architecture Disruption & Differentiation Blockade

* Strict version: Restricted to high- or medium-confidence fusion-specific evidence.

Fusion Gene Name

Mechanism Category

Mechanism PubMed

Tumorigenic Scenarios

Tumorigenic Scenario PubMed

Targeting Points

Targeting PubMed

Mechanism Background

Mechanism Background PubMed

* Extended version: Includes all strict-level fusion evidence plus broader gene-, pathway-, and low-confidence contextual evidence.

Fusion Gene Name

Mechanism Category

Mechanism PubMed

Tumorigenic Scenarios

Tumorigenic Scenario PubMed

Targeting Points

Targeting PubMed

Mechanism Background

Mechanism Background PubMed

Main function of each fusion partner protein. (from UniProt)

Hgene	Tgene
.	.

Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez

Partner	Gene	GO ID	GO term	PubMed ID
Tgene	IFIH1	GO:0009615	response to virus	33727702
Tgene	IFIH1	GO:0016925	protein sumoylation	21156324
Tgene	IFIH1	GO:0032728	positive regulation of interferon-beta production	17600090\|33727702
Tgene	IFIH1	GO:0039530	MDA-5 signaling pathway	17600090\|33727702
Tgene	IFIH1	GO:0045071	negative regulation of viral genome replication	33727702
Tgene	IFIH1	GO:0051607	defense response to virus	21478870\|33727702

Top

Fusion Genomic Features for AGAP1_IFIH1

FusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence) of In-frame fusion genes. FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints.

Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	1-p	p (fusion gene breakpoint)
AGAP1	chr2	236403493	+	IFIH1	chr2	163167443	-	1.93e-07	1.00e+00

FusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence) of 5UTR-3CSD fusion genes (N-truncated cases).

Hgene

Hchr

Hbp

Hstrand

Tgene

Tchr

Tbp

Tstrand

1-p

p (fusion gene breakpoint)

FusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence) of 5CDS-3UTR fusion genes (C-truncated cases).

Hgene

Hchr

Hbp

Hstrand

Tgene

Tchr

Tbp

Tstrand

1-p

p (fusion gene breakpoint)

Distribution of six genomic regulatory feature tracks across a ±5 kb window centered on the fusion breakpoints. We input the breakpoint sequences into AlphaGenome and obtained predicted genome tracks at single-base-pair resolution for each modality by running a single forward pass over the reference sequence. Specifically, for each breakpoint, AlphaGenome processed and returned predicted track data across diverse modalities, which were then averaged across all tracks within each output type and visualized across the ±5 kb window. The left panel shows the 5'-gene breakpoint ±5 kb area, and the right panel shows the 3'-gene breakpoint area, with tracks grouped by category: chromatin accessibility (DNase-seq, ATAC-seq), active transcription (RNA-seq, CAGE), and chromatin binding (ChIP-Histone, ChIP-TF).

Top

Fusion Gene ORF Annotations for AGAP1_IFIH1

Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure.
* Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser.

ORF	Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand
Frame-shift	ENST00000304032	ENST00000263642	AGAP1	chr2	236403493	+	IFIH1	chr2	163167443	-
Frame-shift	ENST00000336665	ENST00000263642	AGAP1	chr2	236403493	+	IFIH1	chr2	163167443	-
Frame-shift	ENST00000409457	ENST00000263642	AGAP1	chr2	236403493	+	IFIH1	chr2	163167443	-
In-frame	ENST00000304032	ENST00000421365	AGAP1	chr2	236403493	+	IFIH1	chr2	163167443	-
In-frame	ENST00000336665	ENST00000421365	AGAP1	chr2	236403493	+	IFIH1	chr2	163167443	-
In-frame	ENST00000409457	ENST00000421365	AGAP1	chr2	236403493	+	IFIH1	chr2	163167443	-

ORFfinder Result Based On The Fusion Transcript Sequences of the In-frame Fusion Genes.

Henst

Tenst

Hgene

Hchr

Hbp

Tgene

Tchr

Tbp

Seq length
(transcript)

Seq length
(peptide)

ORFfinder Result Based On The Fusion Transcript Sequences of the 5UTR-3CDS Fusion Genes for N-Truncated Protein Search.

Henst

Tenst

Hgene

Hchr

Hbp

Tgene

Tchr

Tbp

Seq length
(transcript)

Seq length
(peptide)

ORFfinder Result Based On The Fusion Transcript Sequences of the 5CDS-3UTR Fusion Genes for C-Truncated Protein Search.

Henst

Tenst

Hgene

Hchr

Hbp

Tgene

Tchr

Tbp

Seq length
(transcript)

Seq length
(peptide)

DeepORF Prediction of The Coding Potential Based on The Fusion Transcript Sequence of In-frame Fusion Genes. DeepORF is a Coding Potential Classifier Based on Convolutional Neural Network by Comparing the Real Ribo-seq Data. If the No-coding Score < 0.5 and Coding Score > 0.5, Then The In-frame Fusion Transcript is Predicted as Being Likely Translated.

Henst	Tenst	Hgene	Hchr	Hbp	Tgene	Tchr	Tbp	No-coding score	Coding score
ENST00000304032	ENST00000421365	AGAP1	chr2	236403493	IFIH1	chr2	163167443	1.49e-01	8.51e-01
ENST00000336665	ENST00000421365	AGAP1	chr2	236403493	IFIH1	chr2	163167443	1.49e-01	8.51e-01
ENST00000409457	ENST00000421365	AGAP1	chr2	236403493	IFIH1	chr2	163167443	1.44e-01	8.56e-01

DeepORF Prediction of The Coding Potential Based on The Fusion Transcript Sequence of 5UTR-3CDS Fusion Genes (Potential N-Truncated Proteins).

Henst

Tenst

Hgene

Hchr

Hbp

Tgene

Tchr

Tbp

No-coding score

Coding score

DeepORF Prediction of The Coding Potential Based on The Fusion Transcript Sequence of 5CDS-3UTR Fusion Genes (Potential C-Truncated Proteins).

Henst

Tenst

Hgene

Hchr

Hbp

Tgene

Tchr

Tbp

No-coding score

Coding score

Top

Fusion Protein Retained/Non-Retained Functional Features for AGAP1_IFIH1

Protein Level Annotation from FGviewer
* Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at download page. Minus value of BPloci means that the break pointn is located before the CDS.

- In-frame and retained protein feature among the 13 regional features (visualization across fusion protein length).

AGAP1_IFIH1_chr2-236403493_chr2-163167443.png

- In-frame and retained protein feature among the 13 regional features (texts).

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Protein feature

Protein feature note

Tgene

IFIH1

chr2:236403493

chr2:163167443

ENST00000421365

Q9BYX4

277_289

151.0

222.0

Compositional bias

Low complexity

Tgene

IFIH1

chr2:236403493

chr2:163167443

ENST00000421365

Q9BYX4

641_661

151.0

222.0

Compositional bias

Acidic residues

Tgene

IFIH1

chr2:236403493

chr2:163167443

ENST00000421365

Q9BYX4

316_509

151.0

222.0

Domain

Helicase ATP-binding

Tgene

IFIH1

chr2:236403493

chr2:163167443

ENST00000421365

Q9BYX4

700_882

151.0

222.0

Domain

Helicase C-terminal

Tgene

IFIH1

chr2:236403493

chr2:163167443

ENST00000421365

Q9BYX4

893_1020

151.0

222.0

Domain

RLR CTR

Tgene

IFIH1

chr2:236403493

chr2:163167443

ENST00000421365

Q9BYX4

271_307

151.0

222.0

Region

Disordered

Tgene

IFIH1

chr2:236403493

chr2:163167443

ENST00000421365

Q9BYX4

640_662

151.0

222.0

Region

Disordered

- In-frame and not-retained protein feature among the 13 regional features.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Protein feature

Protein feature note

Hgene

AGAP1

chr2:236403493

chr2:163167443

ENST00000304032

Q9UPQ3

275_289

54.333333333333336

858.0

Compositional bias

Low complexity

Hgene

AGAP1

chr2:236403493

chr2:163167443

ENST00000304032

Q9UPQ3

322_337

54.333333333333336

858.0

Compositional bias

Basic and acidic residues

Hgene

AGAP1

chr2:236403493

chr2:163167443

ENST00000304032

Q9UPQ3

422_449

54.333333333333336

858.0

Compositional bias

Polar residues

Hgene

AGAP1

chr2:236403493

chr2:163167443

ENST00000304032

Q9UPQ3

504_514

54.333333333333336

858.0

Compositional bias

Low complexity

Hgene

AGAP1

chr2:236403493

chr2:163167443

ENST00000304032

Q9UPQ3

524_534

54.333333333333336

858.0

Compositional bias

Basic residues

Hgene

AGAP1

chr2:236403493

chr2:163167443

ENST00000304032

Q9UPQ3

346_588

54.333333333333336

858.0

Domain

Hgene

AGAP1

chr2:236403493

chr2:163167443

ENST00000304032

Q9UPQ3

609_729

54.333333333333336

858.0

Domain

Arf-GAP

Hgene

AGAP1

chr2:236403493

chr2:163167443

ENST00000304032

Q9UPQ3

67_241

54.333333333333336

858.0

Domain

GLD

Hgene

AGAP1

chr2:236403493

chr2:163167443

ENST00000304032

Q9UPQ3

267_343

54.333333333333336

858.0

Region

Disordered

Hgene

AGAP1

chr2:236403493

chr2:163167443

ENST00000304032

Q9UPQ3

406_449

54.333333333333336

858.0

Region

Disordered

Hgene

AGAP1

chr2:236403493

chr2:163167443

ENST00000304032

Q9UPQ3

496_547

54.333333333333336

858.0

Region

Disordered

Hgene

AGAP1

chr2:236403493

chr2:163167443

ENST00000304032

Q9UPQ3

66_276

54.333333333333336

858.0

Region

Note=Small GTPase-like

Hgene

AGAP1

chr2:236403493

chr2:163167443

ENST00000304032

Q9UPQ3

768_797

54.333333333333336

858.0

Repeat

Note=ANK 1

Hgene

AGAP1

chr2:236403493

chr2:163167443

ENST00000304032

Q9UPQ3

801_830

54.333333333333336

858.0

Repeat

Note=ANK 2

Hgene

AGAP1

chr2:236403493

chr2:163167443

ENST00000304032

Q9UPQ3

624_647

54.333333333333336

858.0

Zinc finger

C4-type

Tgene

IFIH1

chr2:236403493

chr2:163167443

ENST00000421365

Q9BYX4

110_190

151.0

222.0

Domain

Note=CARD 2

Tgene

IFIH1

chr2:236403493

chr2:163167443

ENST00000421365

Q9BYX4

7_97

151.0

222.0

Domain

Note=CARD 1

- Retained PPIs in in-frame fusion.

Partner

Hgene

Hbp

Tgene

Tbp

ENST

UniProt

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Still interaction with

- Lost PPIs in in-frame fusion.

Partner

Hgene

Hbp

Tgene

Tbp

ENST

UniProt

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Interaction lost with

Top

Fusion Transcript Sequence for AGAP1_IFIH1

In-frame Fusion Transcript Sequences.

>AGAP1_IFIH1_ENST00000304032_ENST00000421365_236403493_163167443 length=1530nt 
 Breakpoint=743nt
CGCGGCTTGCAAGGCGCCTGCGACTCGGTCCCAGGTCGGCGGGCGGCGCACGGCGGGCTCGCGCGGGGGCCCCGGCGCGCCGGGCGGCGCAGTACGCAGCGCGCGGACCCACGCCACGGCCAGGAGCCCAGAGCAGCGCGGCCACACTGC
CCAGGGGTCGGCCCTCGGCCCCGGCGCTCGGAGCGCGGCGGCTGCCTGGGCTTTAATGGCTGCTCCGCGGAGCAGCGCCTAGGGCTGGAAGGCGGCTGCGGCTCAGGAAGTCACCCGAGCAAGCCTCCTTCGGGGCCGGCCGCACCCGCC
GCGGCGCGCTCCATGGGGGCGCGCTCCCCCCGGGCGGCCCGCTGACCCGGGACGCCGGGGCCCGCTCGCTCGCCGGCCGCGCGTCCCGGCCATGAACTGAGCCCGCGGGCCAGCCCCGCGCCTGCTCCGCCCGCGCCTTTCTTCTCGCGC
CTCCTCCGCCCGCCGCCGGCGGGCCCGGCTCCCCGGGGGCTGCGGCGCCCCGGGCTCGGCGGCCCGCGGGCCCCGGGGCGCGGGGCGGCGGCGGCGGGGGGCGCGCGGCTCCGGGCGCGGCGCCTGCACCATGAACTACCAGCAGCAGCT
GGCCAACTCGGCTGCCATCCGGGCCGAGATCCAGCGCTTCGAGTCGGTCCACCCCAACATCTACTCCATCTACGAGCTGCTGGAGCGCGTGGAGGAGCCGGTGCTGCAGAACCAGATCCGGGAGCACGTCATCGCCATCGAAGATTGCTG
CTGCAGAAAACAATGGAAATGAATCAGGTGTAAGAGAGCTACTAAAAAGGATTGTGCAGAAAGAAAACTGGTTCTCTGCATTTCTGAATGTTCTTCGTCAAACAGGAAACAATGAACTTGTCCAAGAGTTAACAGGCTCTGATTGCTCAG
AAAGCAATGCAGGTATTTGTAATTTTACTGAGGAAGATTCTTCAAATTCTGCCTAGTGATTGAGAATTCAATAAAGCAGAAAGACACAATGCTAAACACCAAGATTTTTAGAATCAAAATTTTAAGAGTGGAACATATGTGATAGATCAT
CTATTTTATCACCTTAACAAATGAGGAAATTGATGCCTGGGAAAATATCAACTGATCAAAGACCATTTTTCATCCAACCAACACTCTTTCTACTACCTTATTTTAAAAACAATATGACTACCAGAAATTTTATCAAGATTATGTAACATT
AAATATACACAAATACATTGGAAGAAAGTATTTTAGTGGTTATAAAAAATCTGCTGCATATTCTTCTGAACATTTTTATACATTTTAAGCAATGTATTAAGCATTTGATAAAAGGATTGTTTTGTCAATATATCTCAACCTTACCTAATG
TGAGATTTTAAACAGCATTCAATAATAGTAATAACATAACATTTTATAGCTCCTTCTCCTACATTATTTGTAAATCTCACTTAAACTGCTATCTTATTTTTCTTTTCGTAGTATGCATCCTATGTTTCCAAAAATATCATATGAAAGACA
AATTGAAAGTTAACTATTAATTAATTATAA

>AGAP1_IFIH1_ENST00000336665_ENST00000421365_236403493_163167443 length=1530nt 
 Breakpoint=743nt
CGCGGCTTGCAAGGCGCCTGCGACTCGGTCCCAGGTCGGCGGGCGGCGCACGGCGGGCTCGCGCGGGGGCCCCGGCGCGCCGGGCGGCGCAGTACGCAGCGCGCGGACCCACGCCACGGCCAGGAGCCCAGAGCAGCGCGGCCACACTGC
CCAGGGGTCGGCCCTCGGCCCCGGCGCTCGGAGCGCGGCGGCTGCCTGGGCTTTAATGGCTGCTCCGCGGAGCAGCGCCTAGGGCTGGAAGGCGGCTGCGGCTCAGGAAGTCACCCGAGCAAGCCTCCTTCGGGGCCGGCCGCACCCGCC
GCGGCGCGCTCCATGGGGGCGCGCTCCCCCCGGGCGGCCCGCTGACCCGGGACGCCGGGGCCCGCTCGCTCGCCGGCCGCGCGTCCCGGCCATGAACTGAGCCCGCGGGCCAGCCCCGCGCCTGCTCCGCCCGCGCCTTTCTTCTCGCGC
CTCCTCCGCCCGCCGCCGGCGGGCCCGGCTCCCCGGGGGCTGCGGCGCCCCGGGCTCGGCGGCCCGCGGGCCCCGGGGCGCGGGGCGGCGGCGGCGGGGGGCGCGCGGCTCCGGGCGCGGCGCCTGCACCATGAACTACCAGCAGCAGCT
GGCCAACTCGGCTGCCATCCGGGCCGAGATCCAGCGCTTCGAGTCGGTCCACCCCAACATCTACTCCATCTACGAGCTGCTGGAGCGCGTGGAGGAGCCGGTGCTGCAGAACCAGATCCGGGAGCACGTCATCGCCATCGAAGATTGCTG
CTGCAGAAAACAATGGAAATGAATCAGGTGTAAGAGAGCTACTAAAAAGGATTGTGCAGAAAGAAAACTGGTTCTCTGCATTTCTGAATGTTCTTCGTCAAACAGGAAACAATGAACTTGTCCAAGAGTTAACAGGCTCTGATTGCTCAG
AAAGCAATGCAGGTATTTGTAATTTTACTGAGGAAGATTCTTCAAATTCTGCCTAGTGATTGAGAATTCAATAAAGCAGAAAGACACAATGCTAAACACCAAGATTTTTAGAATCAAAATTTTAAGAGTGGAACATATGTGATAGATCAT
CTATTTTATCACCTTAACAAATGAGGAAATTGATGCCTGGGAAAATATCAACTGATCAAAGACCATTTTTCATCCAACCAACACTCTTTCTACTACCTTATTTTAAAAACAATATGACTACCAGAAATTTTATCAAGATTATGTAACATT
AAATATACACAAATACATTGGAAGAAAGTATTTTAGTGGTTATAAAAAATCTGCTGCATATTCTTCTGAACATTTTTATACATTTTAAGCAATGTATTAAGCATTTGATAAAAGGATTGTTTTGTCAATATATCTCAACCTTACCTAATG
TGAGATTTTAAACAGCATTCAATAATAGTAATAACATAACATTTTATAGCTCCTTCTCCTACATTATTTGTAAATCTCACTTAAACTGCTATCTTATTTTTCTTTTCGTAGTATGCATCCTATGTTTCCAAAAATATCATATGAAAGACA
AATTGAAAGTTAACTATTAATTAATTATAA

>AGAP1_IFIH1_ENST00000409457_ENST00000421365_236403493_163167443 length=1548nt 
 Breakpoint=761nt
GGCGCTCGGAGCGGGCTCCGCGGCTTGCAAGGCGCCTGCGACTCGGTCCCAGGTCGGCGGGCGGCGCACGGCGGGCTCGCGCGGGGGCCCCGGCGCGCCGGGCGGCGCAGTACGCAGCGCGCGGACCCACGCCACGGCCAGGAGCCCAGA
GCAGCGCGGCCACACTGCCCAGGGGTCGGCCCTCGGCCCCGGCGCTCGGAGCGCGGCGGCTGCCTGGGCTTTAATGGCTGCTCCGCGGAGCAGCGCCTAGGGCTGGAAGGCGGCTGCGGCTCAGGAAGTCACCCGAGCAAGCCTCCTTCG
GGGCCGGCCGCACCCGCCGCGGCGCGCTCCATGGGGGCGCGCTCCCCCCGGGCGGCCCGCTGACCCGGGACGCCGGGGCCCGCTCGCTCGCCGGCCGCGCGTCCCGGCCATGAACTGAGCCCGCGGGCCAGCCCCGCGCCTGCTCCGCCC
GCGCCTTTCTTCTCGCGCCTCCTCCGCCCGCCGCCGGCGGGCCCGGCTCCCCGGGGGCTGCGGCGCCCCGGGCTCGGCGGCCCGCGGGCCCCGGGGCGCGGGGCGGCGGCGGCGGGGGGCGCGCGGCTCCGGGCGCGGCGCCTGCACCAT
GAACTACCAGCAGCAGCTGGCCAACTCGGCTGCCATCCGGGCCGAGATCCAGCGCTTCGAGTCGGTCCACCCCAACATCTACTCCATCTACGAGCTGCTGGAGCGCGTGGAGGAGCCGGTGCTGCAGAACCAGATCCGGGAGCACGTCAT
CGCCATCGAAGATTGCTGCTGCAGAAAACAATGGAAATGAATCAGGTGTAAGAGAGCTACTAAAAAGGATTGTGCAGAAAGAAAACTGGTTCTCTGCATTTCTGAATGTTCTTCGTCAAACAGGAAACAATGAACTTGTCCAAGAGTTAA
CAGGCTCTGATTGCTCAGAAAGCAATGCAGGTATTTGTAATTTTACTGAGGAAGATTCTTCAAATTCTGCCTAGTGATTGAGAATTCAATAAAGCAGAAAGACACAATGCTAAACACCAAGATTTTTAGAATCAAAATTTTAAGAGTGGA
ACATATGTGATAGATCATCTATTTTATCACCTTAACAAATGAGGAAATTGATGCCTGGGAAAATATCAACTGATCAAAGACCATTTTTCATCCAACCAACACTCTTTCTACTACCTTATTTTAAAAACAATATGACTACCAGAAATTTTA
TCAAGATTATGTAACATTAAATATACACAAATACATTGGAAGAAAGTATTTTAGTGGTTATAAAAAATCTGCTGCATATTCTTCTGAACATTTTTATACATTTTAAGCAATGTATTAAGCATTTGATAAAAGGATTGTTTTGTCAATATA
TCTCAACCTTACCTAATGTGAGATTTTAAACAGCATTCAATAATAGTAATAACATAACATTTTATAGCTCCTTCTCCTACATTATTTGTAAATCTCACTTAAACTGCTATCTTATTTTTCTTTTCGTAGTATGCATCCTATGTTTCCAAA
AATATCATATGAAAGACAAATTGAAAGTTAACTATTAATTAATTATAA

N-Truncated Transcript (5UTR-3CDS) Sequences

C-Truncated Transcript (5CDS-3UTR) Sequences

Top

Fusion Protein Sequence for AGAP1_IFIH1

In-frame Fusion Protein Sequences.

N-Truncated Protein (5UTR-3CDS) Sequences

C-Truncated Protein (5CDS-3UTR) Sequences

Top

Personalized Fusion Protein Sequence for AGAP1_IFIH1

TCGA Kinase/DNA-binding Domain Mutated Fusion Protein Sequences

Num

Gene Group

Domain Loci

Fusion Protein ID

Fusion Gene Name

Partner

Mutated Residue in WT Protein

Seq. Length

Mutated Residue in Fusion Protein

CCLE Kinase/DNA-binding Domain Mutated Fusion Protein Sequences

Num

Gene Group

Domain Loci

Fusion Protein ID

Fusion Gene Name

Partner

Mutated Residue in WT Protein

Seq. Length

Mutated Residue in Fusion Protein

TCGA All Mutated Fusion Protein Sequences

Fusion Protein ID

Sample ID

Mutated Partner

AAchange in WT

Seq. Length

AAchange in Fusion

CCLE All Mutated Fusion Protein Sequences

Fusion Protein ID

Sample ID

Mutated Partner

AAchange in WT

Seq. Length

AAchange in Fusion

Top

Fusion Gene Exprssed Samples for AGAP1_IFIH1

RNA-seq based fusion gene expressed samples.

Source	Study	Disease	Sample	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand
ChimerDB		OV	TCGA-24-2298-01A	AGAP1	chr2	236403493	+	IFIH1	chr2	163167443	-
WashU		OV	TCGA-24-2298-01A	AGAP1	chr2	236403493	+	IFIH1	chr2	163167443	-

DNA-seq based fusion gene expressed samples.

Source

Study

Disease

Sample

Hgene

Hchr

Hbp

Hstrand

Tgene

Tchr

Tbp

Tstrand

SV type

Top

Related Drugs for AGAP1_IFIH1

PubMed Abstract Search With ['A-B' AND 'drug'], ['A::B' AND 'drug']
* For more details on the Studied, Reported, Approved Drugs targeting this fusion gene, Go to FusionPub.

PMID

Fusion Gene Name

Drug

Study Title

Drugs targeting genes involved in this fusion gene.
(DrugBank Version 5.1.8 2021-05-08)

Partner

Gene

UniProtAcc

DrugBank ID

Drug name

Drug activity

Drug type

Drug status